Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease (Q37492987)

20 August 2017

1 reference

title

Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease (English)

1 reference

20 August 2017

1 reference

Ray Borrow

1 reference

20 August 2017

Carl E Frasch

1 reference

20 August 2017

John Donnelly

1 reference

20 August 2017

language of work or name

English

0 references

publication date

21 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

27 Suppl 2

1 reference

20 August 2017

page(s)

B112-6

1 reference

Uncloaking the meningococcus: dynamics of carriage and disease

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Development of natural immunity to Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

THE RESULTS OF THE SERUM TREATMENT IN THIRTEEN HUNDRED CASES OF EPIDEMIC MENINGITIS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Human immunity to the meningococcus. I. The role of humoral antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Human immunity to the meningococcus. II. Development of natural immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Escherichia coli K51 and K93 capsular polysaccharides are crossreactive with the group A capsular polysaccharide of Neisseria meningitidis. Immunochemical, biological, and epidemiological studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Naturally-acquired immunity to Neisseria meningitidis group A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Lack of Immunity in University Students before an Outbreak of Serogroup C Meningococcal Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Prevention of Meningococcal Disease by Group C Polysaccharide Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Importance of complement source in measuring meningococcal bactericidal titers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Impact of meningococcal C conjugate vaccine in the UK.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Effectiveness Analyses May Underestimate Protection of Infants after Group C Meningococcal Immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

A prospective study of the effectiveness of the New Zealand meningococcal B vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Surrogate end points in clinical trials: are we being misled?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

A framework for assessing immunological correlates of protection in vaccine trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

Bacillus pumilus polysaccharide cross-reactive with meningococcal group A polysaccharide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.065

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2009.04.065

1 reference

20 August 2017

1 reference